Skip to main content

Day: January 26, 2022

Cannabis Global CEO Discusses Corporate Momentum in Audio Interview with SmallCapVoice.com

Arman Tabatabaei, CEO of Cannabis Global Featured on SmallCapVoice.com, Inc.Cannabis Global CEO Discusses Corporate Momentum in Audio Interview with SmallCapVoice.comAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) — SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Cannabis Global Inc. (OTC Pink: CBGL) to discuss the Company’s rapid growth and competitive advantages in the cannabis market. Speaking with SCV’s Stuart Smith, Cannabis Global CEO Arman Tabatabaei dives into the Company’s financial performance and expectations for the current quarter. “We’re pretty proud of the way we’ve been able to conduct business over the past couple of quarters, as it’s very clear that we’re growing at a very good pace,” he says, referencing strong growth in revenues and total...

Continue reading

Synaptics Delivers First True Wireless Docking Experience

Reference design enables frictionless universal docking over Wi-Fi 6/6E with secure connect-on-approach and dual-4K display support SAN JOSE, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced the Gemini reference design that delivers the world’s first true Wi-Fi 6/6E wireless docking experience for notebook and laptop PC users. Gemini comprises a unique suite of tightly coupled Synaptics hardware and software elements that securely connect with a docking station or wirelessly enabled monitor when brought within a preset range. It does so with full dual-4K display capability and ultra-low latency that is indistinguishable from wired connections. Gemini was demonstrated at CES 2022. “The game-changing experience that Gemini presents derives from Synaptics’ approach to innovation that...

Continue reading

ManTech Awarded $88 Million Task Order for Combat Weapons Systems Support by Naval Surface Warfare Center Dahlgren Division

David Hathaway, Executive Vice President and General Manager, ManTech’s Defense Sector“Naval Surface Warfare Center Dahlgren’s continued reliance on ManTech is recognition of our deep bench strength and exceptional teams of test and evaluation experts.”HERNDON, Va., Jan. 26, 2022 (GLOBE NEWSWIRE) — The Naval Surface Warfare Center Dahlgren Division (NSWCDD) has awarded ManTech (Nasdaq: MANT) a five-year $88 million IDIQ task order to provide Test and Evaluation (T&E) support for U.S. Navy weapons and combat systems. Under this successful recompete, ManTech will provide comprehensive T&E for software programs and safety certification of U.S. Navy weapons and combat systems programs, including the Aegis Combat System, Aegis Ballistic Missile Defense (BMD) System, Ship Self-Defense System (SSDS) Aircraft...

Continue reading

Aemetis Completes 7-mile Pipeline to Transport Biogas from Five Dairy Digesters to RNG Production Facility

Company Constructing 32-mile Biogas Pipeline Extension for Dairy Renewable Natural Gas Project CUPERTINO, CA, Jan. 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Aemetis, Inc. (NASDAQ: AMTX) announced today that its subsidiary Aemetis Biogas has completed an additional seven miles of underground pipeline to transport biogas from five new dairy digesters to the centralized Renewable Natural Gas upgrading facility located at the Aemetis Keyes biofuels plant.  Including the four miles of biogas pipeline commissioned in late 2020, Aemetis has now installed more than 11 miles of pipeline and is on track to complete the 36-mile biogas pipeline network in 2022. Construction crews are now working on an additional 25 miles of pipeline spanning Stanislaus and Merced Counties to transport biogas for Phases 2 and 3 of the project. ...

Continue reading

Verizon Business and Atos to power industry-leading predictive analytics 5G edge solution

Press Release Verizon Business and Atos to power industry-leading predictive analytics 5G edge solution New York, N.Y., and Paris, France, January 26, 2022 – Verizon Business and Atos today announce an industry-leading partnership to power intelligent IoT solutions with private 5G multi-access edge computing for businesses, government and communities worldwide. The 5G edge solution will transform the way companies can leverage predictive analytics, allowing them to improve operational efficiency, mitigate risk and increase revenue. Combining the expertise of Verizon and Atos, organizations will be able to create immersive digital experiences that fully exercise 5G environments on the edge of their networks, representing the next breakthrough in business value. The Verizon-Atos solution provides an end-to-end architecture that includes...

Continue reading

Taboola Launches “Homepage For You” Artificial Intelligence Technology, Empowering Editors to Make Homepages as Personalized and Engaging as the World’s Top Social Apps; Offering Drives More Than 30% Increase in CTRs

Leading publishers McClatchy, The Independent, Estado de Minas Among Early Users; Homepage For You Bolsters Taboola Newsroom Offering to Help Editors Compete Against Social Networks Through PersonalizationTaboola Homepage For YouHomepage For You helps editors power their homepages, their most visited and prominent section of their website, to capture attention by leveraging Taboola’s advanced A.I. and proven recommendation platform–the same technology used by over 9,000 global publishers.NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) — Taboola, a global leader in powering recommendations for the open web, helping people discover things they may like, today announced a new milestone for its publisher platform that adds A.I. to power editorial recommendations on publisher homepages, an offering already being used...

Continue reading

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company BURLINGTON, Mass. and JERUSALEM, Jan. 26, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the addition of Professor Markus Heilig, M.D., Ph.D., to BrainsWay’s scientific advisory board. “It is my distinct pleasure to welcome Professor Heilig to our scientific advisory board,” said Christopher von Jako, Ph.D., President and CEO of BrainsWay. “His extensive body of research has helped lay the foundation upon which we continue to build clinical advancements, including his recent results treating alcohol dependent patients with Deep TMS™. As a luminary in the field, Professor...

Continue reading

Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers

Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel First study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM dataSAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared...

Continue reading

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the first chronic hepatitis B (CHB) patient has been dosed in the multiple ascending dose (MAD) portion of Study ALG-020572-401 (NCT05001022) which is evaluating antisense oligonucleotide (ASO) ALG-020572. “We are pleased to have initiated the MAD phase of this study in CHB patients,” said Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos....

Continue reading

ST. JAMES GOLD CORP. (TSX-V: LORD) ADDS SENIOR MINING EXECUTIVE TERENCE F. COUGHLAN, P.GEO, TO ITS BOARD OF ADVISORS

St. James Gold Corp.Terence F. Coughlan, P.Geo, has joined the company’s Board of Advisors.Vancouver, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) is pleased to announce that Terence F. Coughlan, P.Geo, has joined the company’s Board of Advisors. Mr. Coughlan’s appointment follows the Company’s recent appointment of Sean Tufford as director of business development. Together, they bring a track record of success and significant mining experience to the Company at a time of transformative development in Newfoundland and the Yukon. Actively involved in the mineral resource industry since 1984, Mr. Coughlan brings with him a nearly 40-year record of success in mineral exploration, operations and corporate development. The founding Chief...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.